Crinetics Pharmaceuticals grants stock options to new employees under 2021 Inducement Plan.

From GlobeNewswire: 2025-01-10 17:15:15

Crinetics Pharmaceuticals, Inc. granted non-qualified stock options to new employees, with 96,100 shares for sixteen non-executive employees and 100,000 shares for one executive employee. The options were granted under the 2021 Inducement Plan at an exercise price of $40.59 per share, vesting over four years. Crinetics is a pharmaceutical company focused on novel therapeutics for endocrine diseases, with lead candidates paltusotine for acromegaly and carcinoid syndrome, and atumelnant for congenital adrenal hyperplasia and Cushing’s disease. All drug candidates are orally delivered small molecules developed in-house. For more information, contact Gayathri Diwakar at [email protected] or Natalie Badillo at [email protected].



Read more at GlobeNewswire: Crinetics Pharmaceuticals Announces January 2025 Inducement